FindTrial
Sign In

Pharmacokinetic models of prolonged infusion of dexmedetomidine in critically ill patients

External validation of pharmacokinetic models of prolonged infusion of dexmedetomidine in adult critically ill patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012631
Enrollment
Unknown
Registered
2017-09-05
Start date
2017-09-07
Completion date
Unknown
Last updated
2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical illness

Interventions

Case series:Dexmedetomidine, intravenous 0.1-0.7 mcg/kg/hr Upto 2 weeks, Continuous infusion.

Sponsors

The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients admitted to the Prince of Wales Hospital in Hong Kong expecting to requiring prolonged sedation for more than 24 hours but less than 2 weeks of dexmedetomidine for mechanical ventilation will be included.

Exclusion criteria

Exclusion criteria: The exclusion criteria will include the following: history of intolerance to dexmedetomidine, use of centrally acting a2-agonsits or antagonists (eg. clonidine), need for continuous muscle relaxation, uncompensated circulatory failure (mean arterial pressure 101 µmol/L), acute severe intracranial or spinal neurologic disorder, significant haematological, endocrine, metabolic or gastrointestinal disease, or burn injuries and other injuries requiring regular anaesthesia or surgery.

Design outcomes

Primary

MeasureTime frame
Dexmedetomidine serum concentrations;—

Secondary

MeasureTime frame
Sedation score;—

Countries

China

Contacts

Public ContactAndrew Tse

Department of Anaesthesia and Intensive Care, CUHK

andrewhwtse@link.cuhk.edu.hk+852 3505 2735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026